Catalyst
Slingshot members are tracking this event:
The Medicines Company (MDCO) and Alnylam Pharma (ALNY) Announce Phase 1 Data Evaluating Hypercholesterolemia Treatment Inclisiran (ALN-PCSsc) in The New England Journal of Medicine (NEJM)
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 13, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1, Hypercholesterolemia, Inclisiran, Aln-pcssc, New England Journal Of Medicine, Nejm
